Tunlametinib+PD-1 mAb
SYSUCC-HER2
Phase 2 small_molecule active
Quick answer
Tunlametinib+PD-1 mAb for Gastric Adenocarcinoma is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Gastric Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active